Chemomab jumps on positive liver scarring trial results
Chemomab Therapeutics (Nasdaq: CMMB), which is developing treatments for fibro-inflammatory (scarring) diseases, rose 14% on Friday and is up...
scarring
USFDA approves first treatment for patients with liver scarring due to Fatty Liver Disease – Pharma News
The U.S. Food and Drug Administration (USFDA) has approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis...
